A Comparison of Seroquel vs. Risperidone in Schizophrenia

January 3, 2013 updated by: AstraZeneca
The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States
    • Arizona
      • Phoenix, Arizona, United States
    • California
      • Anaheim, California, United States
      • Cerritos, California, United States
      • Chula Vista, California, United States
      • Glendale, California, United States
      • Hawthorne, California, United States
      • Long Beach, California, United States
      • San Diego, California, United States
      • Santa Ana, California, United States
      • Torrance, California, United States
    • Connecticut
      • Farmington, Connecticut, United States
      • New Haven, Connecticut, United States
    • District of Columbia
      • Washington, District of Columbia, United States
    • Florida
      • Miami, Florida, United States
      • Miami Beach, Florida, United States
      • North Miami, Florida, United States
      • Winter Park, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
    • Illinois
      • Hoffman Estates, Illinois, United States
    • Kansas
      • Prairie Village, Kansas, United States
      • Wichita, Kansas, United States
    • Louisiana
      • New Orleans, Louisiana, United States
      • Shreveport, Louisiana, United States
    • Maryland
      • Baltimore, Maryland, United States
    • Massachusetts
      • Boston, Massachusetts, United States
      • Worcester, Massachusetts, United States
    • Michigan
      • Ann Arbor, Michigan, United States
      • New Baltimore, Michigan, United States
    • Missouri
      • Kansas City, Missouri, United States
      • St. Louis, Missouri, United States
    • Nevada
      • Reno, Nevada, United States
    • New Jersey
      • Clementon, New Jersey, United States
      • Lyons, New Jersey, United States
      • Summit, New Jersey, United States
    • New Mexico
      • Albuquerque, New Mexico, United States
    • New York
      • Bronx, New York, United States
      • Holliswood, New York, United States
      • Montrose, New York, United States
      • New York, New York, United States
      • Oceanside, New York, United States
      • White Plains, New York, United States
    • North Carolina
      • Butner, North Carolina, United States
    • Ohio
      • Beachwood, Ohio, United States
      • Chagrin Falls, Ohio, United States
      • Cincinnati, Ohio, United States
      • Columbus, Ohio, United States
    • Oklahoma
      • Oklahoma City, Oklahoma, United States
    • Pennsylvania
      • Media, Pennsylvania, United States
      • Pittsburgh, Pennsylvania, United States
    • Tennessee
      • Memphis, Tennessee, United States
      • Nashville, Tennessee, United States
    • Texas
      • Austin, Texas, United States
      • Houston, Texas, United States
      • Terrell, Texas, United States
      • Waco, Texas, United States
    • Utah
      • Salt Lake City, Utah, United States
    • Virginia
      • Falls Church, Virginia, United States
      • Richmond, Virginia, United States
      • Virginia Beach, Virginia, United States
    • Washington
      • Kirkland, Washington, United States
      • Tacoma, Washington, United States
      • Vancouver, Washington, United States
    • Wisconsin
      • West Allis, Wisconsin, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria

  • Male / Female, 18-65 years old
  • Schizophrenia (as per DSM IV)

Exclusion Criteria

  • Concurrent use of psychotropic medication
  • Does not fulfill moderately ill on CGI

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2001

Primary Completion (Actual)

September 1, 2002

Study Completion (Actual)

September 1, 2002

Study Registration Dates

First Submitted

May 2, 2002

First Submitted That Met QC Criteria

May 2, 2002

First Posted (Estimate)

May 3, 2002

Study Record Updates

Last Update Posted (Estimate)

January 4, 2013

Last Update Submitted That Met QC Criteria

January 3, 2013

Last Verified

January 1, 2013

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 5077US/0043

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on quetiapine fumarate vs risperidone

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe